The FDA has approved Tecentriq and Tecentriq Hybreza with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III dMMR colon cancer, based on the phase III ATOMIC trial.
The European Commission has approved Enhertu plus pertuzumab as a first-line treatment for HER2-positive metastatic breast cancer, marking AstraZeneca and Daiichi Sankyo’s first new EU regimen in this setting in over a decade, backed by DESTINY-Breast09 data showing a 44% reduction in progression or death risk.
Genentech and Roche have filed a new patent-infringement lawsuit against Biocon in New Jersey federal court, alleging Biocon’s proposed pertuzumab biosimilar infringes patents covering Perjeta, Roche’s blockbuster HER2-positive breast-cancer treatment, the second major U.S. action against Biocon over the same product in 2026.
The APHINITY study’s ten-year follow-up results showed that adjuvant Perjeta® (pertuzumab) added to chemotherapy and Herceptin® (trastuzumab) resulted in a clinically significant survival benefit.
